Atypical antipsychotics: New drugs, new challenges

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 8, 2007, Pages 597-606

  Mathews, Manu ^a   Muzina, David J ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of Research and Education ^*  (United States)

^c Bipolar Disorders Research Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; HUMAN; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; RISK FACTOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIABETES MELLITUS; HUMANS; PSYCHOTIC DISORDERS; RISK FACTORS; RISPERIDONE; WEIGHT GAIN;

EID: 35248838919     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.8.597     Document Type: Article

References (56)

1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists. North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601.
2. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96.
3. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpiride. Amisulpiride Study Group. Am J Psychiatry 1999; 156:610-616.
4. Ho BC, Miller D, Nopoulos P, Andreasen NC. Comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60:658-663.
5. Picker D. Owen RR, Litman RE, Konicki E, Gutierrez R, Rapoport MH. Clinical and biologic response in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353.
6. Verdoux H, Magnin E, Bourgeois M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophr Res 1995; 14:133-139.
7. Seidman LJ, Pepple JR, Faraone SV, et al. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993; 33:575-594.
8. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown M. Neuroleptic drug effects on cognitive functions in schizophrenia. Schizophr Res 1990; 3:211-219.
9. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33:73-85.
10. Kinon BJ, Lieberman JA. Mechanisms of actions of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996; 124:2-34.
11. Baldessarini RJ, Rankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324:746-754.
12. Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158:360-369.
13. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50:873-883.
14. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994; 271:1058-1066.
15. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3:1607-1619.
16. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996; 14:97-105.
17. Tendon R. Neuropharmacologic basis for clozapine's unique profile. Arch Gen Psychiatry 1993; 50:158-159.
18. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: review of recent literature. J Clin Psychopharmacol 1996; 16:177-187.
19. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57(suppl 11):12-25.
20. Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother 2004; 38:313-319.
21. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics. Part II: Adverse effects, drug interactions, and costs. Ann Pharmacother 1999; 33:210-217.
22. Lieberman JA, Stroup TS, McAvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
23. Miyamoto S, Duncan GE, Lieberman JA. Second generation antipsychotics in the treatment of schizophrenia: olanzapine in current issues in the psychopharmacology of schizophrenia. In: Brier A, Tran PV, eds. Current Issues in the Psychopharmacology of Schizophrenia. Philadelphia: Lippincott Williams & Wilkins, 2001:224-242.
24. Kapur S, Zipursky RE, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155:921-928.
25. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696.
26. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(suppl 1):1-93.
27. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993; 112:285-292.
28. Small JG, Kolar MC, Kellams JJ. Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin 2004; 20:1017-1023.
29. Kasper S, Brecher M, Fitton L, Jones AM. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol 2004; 19:281-289.
30. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999: 20:491-505.
31. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol 2001; 39:1-14.
32. Lawler CP, Prideau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20:612-627.
33. Prescribing information for Invega, www.invega.com.
34. Dev V, Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf 2000; 23:295-307.
35. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D. Drugs, neurotransmitters, and schizophrenia: phenothiazines, amphetamines, and enzymes synthesizing psychotomimetic drugs and schizophrenia research. Science 1974: 184:1243-1253.
36. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992; 7:261-284.
37. Duncan GE, Sheltman BE, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 1999; 29:250-264.
38. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-289.
39. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26:903-912.
40. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561-566.
41. Koeller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111:716-723.
42. Koeller EA, Cross JT, Doralswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23:735-744.
43. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157:975-981.
44. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62:19-28.
45. McQuade R, Kostic D, et al. Aripiprazole versus olanzapine in schizophrenia: a 52 week open label extension study. American College of Neuropsychopharmacology 43rd annual meeting; Dec 12-16, 2004; San Juan, Puerto Rico.
46. Resnick HE, Valsania P, Halter JB, Lin X. Differential effects of BMI on diabetes risk among black and white Americans. Diabetes Care 1998; 21:1828-1835.
47. Allison DB, Mentore JL, Heo M, et al. Anti psychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696.
48. Jones B. Weight changes in patients treated with quetiapine. Poster. 8th annual meeting of Neuropsychopharmacology; 1999, Acapulco, Mexico.
49. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-136.
50. Lindenmayer JP, Cozobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290-296.
51. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill patients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161:1837-1847.
52. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59:1021-1026.
53. Tandon R. Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28 (suppl 1):9-26.
54. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002: 167:1269-1270.
55. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170:1395.
56. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330:445.